[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Q: How many CSWI shares did Director Robert M. Swartz sell?

200 shares were sold on 07/01/2025.

Q: At what price were the CSWI shares sold?

The sale price was $284.18 per share.

Q: What is Robert M. Swartz’s remaining CSWI shareholding after the sale?

He now directly owns 12,519 CSWI common shares.

Q: Was the transaction part of a 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 plan adopted on 09/10/2024.

Q: Does the Form 4 report any derivative security transactions?

No, no derivative trades were reported in Table II.

Filing Impact

(High)

Filing Sentiment

(Very Positive)

Form Type

Rhea-AI Filing Summary

CSW Industrials, Inc. (CSWI) Form 4 filing: Director Robert M. Swartz sold 200 shares of common stock on 07/01/2025 at $284.18 per share under a pre-arranged Rule 10b5-1 trading plan adopted on 09/10/2024. After the sale, Swartz retains 12,519 shares, indicating he disposed of roughly 1.6% of his direct holdings. No derivative transactions were reported. The filing reflects normal insider trading disclosure requirements and does not indicate any change in Swartz’s board position or additional transactions.

Positive

Transparent 10b5-1 plan reduces perception of opportunistic insider selling.
Director retains 12,519 shares, maintaining substantial equity alignment.

Negative

Event still constitutes insider selling, which some investors may interpret cautiously, even if minor.

Insights

TL;DR: Small, pre-planned insider sale; minimal impact.

The disposition represents a negligible fraction of the director’s stake and was executed under a 10b5-1 plan, signalling routine portfolio management rather than a valuation call. With more than 12.5k shares still held, alignment with shareholders remains largely intact. The trade size (≈$57k) is immaterial relative to CSWI’s market capitalization, so I consider the informational content neutral for valuation purposes.

TL;DR: Proper 10b5-1 disclosure; governance practices upheld.

The use of a disclosed 10b5-1 plan reduces litigation risk and supports transparency. Signature by an attorney-in-fact and timely Form 4 filing indicate compliance with Section 16 reporting rules. There are no red flags regarding undisclosed derivative positions or significant ownership changes, so the event is corporately routine and not governance-negative.

07/01/2025 - 06:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.0001 par value⁽¹⁾	06/30/2025		P		142,604⁽⁶⁾	A	$44	2,798,795	D⁽²⁾
Common Stock, $0.0001 par value⁽¹⁾	06/30/2025		P		115,783⁽⁶⁾	A	$44	2,219,858	D⁽³⁾
Common Stock, $0.0001 par value⁽¹⁾	06/30/2025		P		58,780⁽⁶⁾	A	$44	353,412	D⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽⁵⁾	$46.47	06/25/2025		A		16,000		⁽⁷⁾	06/24/2035	Common Stock, $0.0001 par value	16,000	$0	16,000	I⁽⁵⁾	See footnote⁽⁵⁾
Pre-Funded Warrants to Purchase Common Stock⁽¹⁾	$0.0001							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.0001 par value	201,546		201,546	D⁽²⁾
Pre-Funded Warrants to Purchase Common Stock⁽¹⁾	$0.0001							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.0001 par value	156,742		156,742	D⁽³⁾
Pre-Funded Warrants to Purchase Common Stock⁽¹⁾	$0.0001							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.0001 par value	550,425		550,425	D⁽²⁾
Pre-Funded Warrants to Purchase Common Stock⁽¹⁾	$0.0001							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.0001 par value	375,856		375,856	D⁽³⁾
Pre-Funded Warrants to Purchase Common Stock⁽¹⁾	$0.0001							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.0001 par value	52,733		52,733	D⁽⁴⁾
Stock Option (Right to Buy)⁽⁵⁾	$31.2							⁽⁹⁾	06/17/2034	Common Stock, $0.0001 par value	16,000		16,000	I⁽⁵⁾	See footnote⁽⁵⁾
Stock Option (Right to Buy)⁽⁵⁾	$20							⁽⁹⁾	08/19/2030	Common Stock, $0.0001 par value	40,127		40,127	I⁽⁵⁾	See footnote⁽⁵⁾
Stock Option (Right to Buy)⁽⁵⁾	$49.1							⁽⁹⁾	06/15/2031	Common Stock, $0.0001 par value	20,063		20,063	I⁽⁵⁾	See footnote⁽⁵⁾
Stock Option (Right to Buy)⁽⁵⁾	$14.18							⁽⁹⁾	06/14/2032	Common Stock, $0.0001 par value	12,000		12,000	I⁽⁵⁾	See footnote⁽⁵⁾
Stock Option (Right to Buy)⁽⁵⁾	$27.67							⁽⁹⁾	06/14/2033	Common Stock, $0.0001 par value	12,000		12,000	I⁽⁵⁾	See footnote⁽⁵⁾

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND L P

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BVF I GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND II LP

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BVF II GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

Biotechnology Value Trading Fund OS LP

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BVF Partners OS Ltd.

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BVF GP HOLDINGS LLC

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

BVF INC/IL

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

1. Name and Address of Reporting Person^*

LAMPERT MARK N

(Last)

(First)

(Middle)

44 MONTGOMERY STREET

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks and Footnotes

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

6. Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share.

7. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.

8. The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

9. The shares subject to the option have fully vested.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

	BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	07/01/2025
	Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	07/01/2025
	BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	07/01/2025
	Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	07/01/2025
	BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	07/01/2025
	BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	07/01/2025
	Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	07/01/2025
	BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	07/01/2025
	BVF Inc., By: /s/ Mark N. Lampert, President	07/01/2025
	/s/ Mark N. Lampert	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many CSWI shares did Director Robert M. Swartz sell?

200 shares were sold on 07/01/2025.

At what price were the CSWI shares sold?

The sale price was $284.18 per share.

What is Robert M. Swartz’s remaining CSWI shareholding after the sale?

He now directly owns 12,519 CSWI common shares.

Was the transaction part of a 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 plan adopted on 09/10/2024.

Does the Form 4 report any derivative security transactions?

No, no derivative trades were reported in Table II.

[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

How many CSWI shares did Director Robert M. Swartz sell?

At what price were the CSWI shares sold?

What is Robert M. Swartz’s remaining CSWI shareholding after the sale?

Was the transaction part of a 10b5-1 trading plan?

Does the Form 4 report any derivative security transactions?

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Latest SEC Filings

KYMR Stock Data

Trending News

[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Insights

Securities Analyst neutral

Corporate Governance Expert neutral

FAQ

How many CSWI shares did Director Robert M. Swartz sell?

At what price were the CSWI shares sold?

What is Robert M. Swartz’s remaining CSWI shareholding after the sale?

Was the transaction part of a 10b5-1 trading plan?

Does the Form 4 report any derivative security transactions?

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Latest SEC Filings

KYMR Stock Data